408 related articles for article (PubMed ID: 32442941)
1. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
Zaidel EJ; Wyss Quintana FS; Sosa Liprandi Á; Mendoza I; Márquez MF; Nuñez E; Barbosa M; Baranchuk A
Medicina (B Aires); 2020; 80(3):271-274. PubMed ID: 32442941
[TBL] [Abstract][Full Text] [Related]
2. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
[TBL] [Abstract][Full Text] [Related]
3. [Potential harms associated with 4-aminoquinoline treatment].
Svensson M
Lakartidningen; 2020 Apr; 117():. PubMed ID: 32365215
[TBL] [Abstract][Full Text] [Related]
4. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].
Tomcsányi J; Tomcsányi K
Orv Hetil; 2020 Apr; 161(17):689-691. PubMed ID: 32324363
[TBL] [Abstract][Full Text] [Related]
5. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
Oren O; Yang EH; Gluckman TJ; Michos ED; Blumenthal RS; Gersh BJ
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008688. PubMed ID: 32436730
[No Abstract] [Full Text] [Related]
6. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Juurlink DN
CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
[No Abstract] [Full Text] [Related]
7. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
Malviya A
Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
[No Abstract] [Full Text] [Related]
8. Of chloroquine and COVID-19.
Touret F; de Lamballerie X
Antiviral Res; 2020 May; 177():104762. PubMed ID: 32147496
[TBL] [Abstract][Full Text] [Related]
9. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
10. COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Halm MA
Am J Crit Care; 2020 Nov; 29(6):489-492. PubMed ID: 32839815
[No Abstract] [Full Text] [Related]
11. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Monzani A; Genoni G; Scopinaro A; Pistis G; Kozel D; Secco GG
Eur J Clin Invest; 2020 Jun; 50(6):e13258. PubMed ID: 32356580
[No Abstract] [Full Text] [Related]
12. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
13. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae.
Hamm BS; Rosenthal LJ
Psychosomatics; 2020; 61(6):597-606. PubMed ID: 32800347
[TBL] [Abstract][Full Text] [Related]
14. Regulators split on antimalarials for COVID-19.
Jaffe S
Lancet; 2020 Apr; 395(10231):1179. PubMed ID: 32278373
[No Abstract] [Full Text] [Related]
15. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Khuroo MS
Int J Antimicrob Agents; 2020 Sep; 56(3):106101. PubMed ID: 32687949
[TBL] [Abstract][Full Text] [Related]
16. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Naksuk N; Lazar S; Peeraphatdit TB
Eur Heart J Acute Cardiovasc Care; 2020 Apr; 9(3):215-221. PubMed ID: 32372695
[TBL] [Abstract][Full Text] [Related]
17. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Yahya AS; Khawaja S; Chukwuma J
Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32441496
[No Abstract] [Full Text] [Related]
18. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
[TBL] [Abstract][Full Text] [Related]
19. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
[No Abstract] [Full Text] [Related]
[Next] [New Search]
